116 related articles for article (PubMed ID: 38227640)
1. The Effect of Renin-Angiotensin System Inhibitors in Patients Undergoing Pancreatic Cancer Resection.
Abe S; Nakai Y; Arita J; Ichida A; Kawaguchi Y; Akamatsu N; Kaneko J; Ijichi H; Koike K; Fujishiro M; Hasegawa K
Pancreas; 2024 Mar; 53(3):e233-e239. PubMed ID: 38227640
[TBL] [Abstract][Full Text] [Related]
2. Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal Adenocarcinoma.
Liu H; Naxerova K; Pinter M; Incio J; Lee H; Shigeta K; Ho WW; Crain JA; Jacobson A; Michelakos T; Dias-Santos D; Zanconato A; Hong TS; Clark JW; Murphy JE; Ryan DP; Deshpande V; Lillemoe KD; Fernandez-Del Castillo C; Downes M; Evans RM; Michaelson J; Ferrone CR; Boucher Y; Jain RK
Clin Cancer Res; 2017 Oct; 23(19):5959-5969. PubMed ID: 28600474
[No Abstract] [Full Text] [Related]
3. Risk factors for early recurrence in patients with pancreatic ductal adenocarcinoma who underwent curative resection.
Murakawa M; Kawahara S; Takahashi D; Kamioka Y; Yamamoto N; Kobayashi S; Ueno M; Morimoto M; Sawazaki S; Tamagawa H; Ohshima T; Yukawa N; Rino Y; Morinaga S
World J Surg Oncol; 2023 Aug; 21(1):263. PubMed ID: 37620940
[TBL] [Abstract][Full Text] [Related]
4. Preoperative prediction of disease-free survival in pancreatic ductal adenocarcinoma patients after R0 resection using contrast-enhanced CT and CA19-9.
Li D; Peng Q; Wang L; Cai W; Liang M; Liu S; Ma X; Zhao X
Eur Radiol; 2024 Jan; 34(1):509-524. PubMed ID: 37507611
[TBL] [Abstract][Full Text] [Related]
5. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.
Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D
Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639
[TBL] [Abstract][Full Text] [Related]
6. Post-adjuvant chemotherapy CA19-9 levels predict prognosis in patients with pancreatic ductal adenocarcinoma: A retrospective cohort study.
Imaoka H; Shimizu Y; Senda Y; Natsume S; Mizuno N; Hara K; Hijioka S; Hieda N; Tajika M; Tanaka T; Ishihara M; Niwa Y; Yamao K
Pancreatology; 2016; 16(4):658-64. PubMed ID: 27178104
[TBL] [Abstract][Full Text] [Related]
7. The use of angiotensin system inhibitors correlates with longer survival in resected pancreatic adenocarcinoma patients.
Liu H; Nassour I; Lebowitz S; D'Alesio M; Hampton E; Desilva A; Hammad A; AlMasri S; Khachfe HH; Singhi A; Bahary N; Lee K; Zureikat A; Paniccia A
HPB (Oxford); 2023 Mar; 25(3):320-329. PubMed ID: 36610939
[TBL] [Abstract][Full Text] [Related]
8. Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX.
Lee SH; Hwang DW; Yoo C; Kim KP; Kang S; Jeong JH; Oh D; Song TJ; Lee SS; Park DH; Seo DW; Park JH; Song KB; Lee JH; Lee W; Park Y; Kwak BJ; Chang HM; Ryoo BY; Kim SC
Cancer Res Treat; 2023 Jul; 55(3):956-968. PubMed ID: 36915253
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of para-aortic lymph node metastasis in pancreatic ductal adenocarcinoma.
Murakami Y; Uemura K; Sudo T; Hashimoto Y; Yuasa Y; Sueda T
World J Surg; 2010 Aug; 34(8):1900-7. PubMed ID: 20376442
[TBL] [Abstract][Full Text] [Related]
10. Postoperative prognosis of pancreatic cancer with para-aortic lymph node metastasis: a multicenter study on 822 patients.
Sho M; Murakami Y; Motoi F; Satoi S; Matsumoto I; Kawai M; Honda G; Uemura K; Yanagimoto H; Kurata M; Fukumoto T; Akahori T; Kinoshita S; Nagai M; Nishiwada S; Unno M; Yamaue H; Nakajima Y
J Gastroenterol; 2015 Jun; 50(6):694-702. PubMed ID: 25341657
[TBL] [Abstract][Full Text] [Related]
11. [Surgical therapy of pancreatic cancer - 5 years survival].
Loveček M; Skalický P; Klos D; Neoral Č; Ehrmann J; Zapletalová J; Švébišová H; Yogeswara T; Ghothim M; Vrba R; Havlík R
Rozhl Chir; 2015 Nov; 94(11):470-6. PubMed ID: 26766155
[TBL] [Abstract][Full Text] [Related]
12. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.
Gbolahan OB; Tong Y; Sehdev A; O'Neil B; Shahda S
BMC Cancer; 2019 May; 19(1):468. PubMed ID: 31101022
[TBL] [Abstract][Full Text] [Related]
13. Preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after curative intent surgical resection.
Kim NH; Kim HJ
Hepatobiliary Pancreat Dis Int; 2018 Oct; 17(5):450-455. PubMed ID: 30237091
[TBL] [Abstract][Full Text] [Related]
14. Oncologic resection of pancreatic cancer with isolated liver metastasis: Favorable outcomes in select patients.
Nagai M; Wright MJ; Ding D; Thompson ED; Javed AA; Weiss MJ; Hruban RH; Yu J; Burkhart RA; He J; Cameron JL; Wolfgang CL; Burns WR
J Hepatobiliary Pancreat Sci; 2023 Aug; 30(8):1025-1035. PubMed ID: 36652559
[TBL] [Abstract][Full Text] [Related]
15. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios.
Asari S; Matsumoto I; Toyama H; Shinzeki M; Goto T; Ishida J; Ajiki T; Fukumoto T; Ku Y
Surg Today; 2016 May; 46(5):583-92. PubMed ID: 26108488
[TBL] [Abstract][Full Text] [Related]
16. Survival impact of distal pancreatectomy with en bloc celiac axis resection combined with neoadjuvant chemotherapy for borderline resectable or locally advanced pancreatic body carcinoma.
Murakami Y; Nakagawa N; Kondo N; Hashimoto Y; Okada K; Seo S; Otsuka H
Pancreatology; 2021 Apr; 21(3):564-572. PubMed ID: 33526385
[TBL] [Abstract][Full Text] [Related]
17. Prognosis following surgical bypass compared with laparotomy alone in unresectable pancreatic adenocarcinoma.
Insulander J; Sanjeevi S; Haghighi M; Ivanics T; Analatos A; Lundell L; Del Chiaro M; Andrén-Sandberg Å; Ansorge C
Br J Surg; 2016 Aug; 103(9):1200-8. PubMed ID: 27250937
[TBL] [Abstract][Full Text] [Related]
18. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis.
Sugimoto M; Takahashi N; Farnell MB; Smyrk TC; Truty MJ; Nagorney DM; Smoot RL; Chari ST; Carter RE; Kendrick ML
J Surg Oncol; 2019 Nov; 120(6):976-984. PubMed ID: 31452208
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Value of Adjuvant Chemotherapy Following Pancreaticoduodenectomy in Elderly Patients With Pancreatic Cancer.
Shin SH; Park Y; Hwang DW; Song KB; Lee JH; Kwon J; Yoo C; Alshammary S; Kim SC
Anticancer Res; 2019 Feb; 39(2):1005-1012. PubMed ID: 30711988
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcomes following en bloc resection for pancreatic ductal adenocarcinoma of the head with portomesenteric venous invasion.
Han S; Choi DW; Choi SH; Heo JS; Han IW; You YH
Asian J Surg; 2021 Jan; 44(1):313-320. PubMed ID: 32972828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
